Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 23, 2021

Primary Completion Date

November 14, 2023

Study Completion Date

November 14, 2024

Conditions

Advanced Solid Tumors

Interventions

DRUG

BAT6026

Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result

Trial Locations (1)

Sun Yat-sen University Cancer Center, Guangzhou